News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Spero Therapeutics
NEWS
JOBS
IN THE PRESS
NEWS
Genetown
SEC Filings Reveal GlaxoSmithKline’s 13% Stake in This Massachusetts Biotech
A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.
November 17, 2017
·
3 min read
·
Mark Terry
Genetown
Backed by Google, Cambridge’s Spero Nabs $51.7 Million Series C
March 8, 2017
·
2 min read
Business
Top 20 Life Science Startups to Watch in the U.S.
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
January 26, 2016
·
15 min read
·
Mark Terry
Business
What You Need to Know About Spero
December 2, 2015
·
3 min read
Business
Merck & Co., New England Patriots Owner Wager $30 Million on Cambridge Startup, Spero
June 8, 2015
·
4 min read
AWARDS
JOBS
Currently, there are no jobs for this company on BioSpace
Browse all jobs
here
Oops!
There was an issue retrieving the jobs list. Please reload the page to view more jobs.
Title
Location
Company Name
Desc
View details
IN THE PRESS
Press Releases
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
December 22, 2025
·
3 min read
Press Releases
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 28, 2025
December 1, 2025
·
1 min read
Press Releases
Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update
November 14, 2025
·
8 min read
Press Releases
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
November 4, 2025
·
1 min read
Press Releases
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
October 21, 2025
·
11 min read
Press Releases
Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek
October 15, 2025
·
5 min read
Press Releases
Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update
August 12, 2025
·
10 min read
Press Releases
Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025
August 6, 2025
·
1 min read
Press Releases
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
May 28, 2025
·
9 min read
Press Releases
Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update
May 14, 2025
·
8 min read
